DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
UPDATE STATEMENT

A Toxicological Profile for Radon, Draft for Public Comment was released in September 2008. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences (proposed)/
Environmental Toxicology Branch (proposed)
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333
This page is intentionally blank.
FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the toxic substances each profile describes. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. A health effects summary describes the adequacy of information to determine a substance's health effects. ATSDR identifies data needs that are significant to protection of public health.

Each profile:

(A) Examines, summarizes, and interprets available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;

(B) Determines whether adequate information on the health effects of each substance is available or being developed to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and

(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are federal, state, and local health professionals; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists also have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Christopher J. Portier, Ph.D.
Assistant Administrator
Agency for Toxic Substances and Disease Registry
*Legislative Background*

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:
- Section 1.6 How Can (Chemical X) Affect Children?
- Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
- Section 3.7 Children’s Susceptibility
- Section 6.6 Exposures of Children

Other Sections of Interest:
- Section 3.8 Biomarkers of Exposure and Effect
- Section 3.11 Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)  Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov  Internet: http://www.atsdr.cdc.gov

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-CDC-INFO (800-232-4636) or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. Department of Energy, the World Health Organization, and the International Atomic Energy Agency in the medical management of radiation accidents. A 24-hour emergency response program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, consults, or assists in the response to all kinds of radiation accidents. Contact: Oak Ridge Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 • Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for REAC/TS) • e-mail: cooleyp@orau.gov • website (including emergency medical guidance): http://www.orau.gov/reacts/default.htm

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aaec.org/.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and
This page is intentionally blank.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Sam Keith, M.S., C.H.P.
John R. Doyle, M.P.A.
Carolyn Harper, Ph.D.
Moiz Mumtaz, Ph.D.
Oscar Tarrago, M.D., M.P.H., C.H.E.S.
ATSDR, Division of Toxicology and Human Health Sciences (proposed), Atlanta, GA

David W. Wohlers, Ph.D.
Gary L. Diamond, Ph.D.
Mario Citra, Ph.D.
Lynn E. Barber, M.S.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

3. Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

This page is intentionally blank.
PEER REVIEW

A peer review panel was assembled in 2008 for radon. The panel consisted of the following members:

1. R. William Field, Ph.D., M.S., Professor, College of Public Health, Department of Occupational and Environmental Health and Department of Epidemiology, University of Iowa, Iowa City, Iowa;

2. Naomi H. Harley, Ph.D., Research Professor, Department of Environmental Medicine, New York University School of Medicine, New York, New York; and

3. Jonathan Samet, M.D., Professor and Chairman, Department of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland.

These experts collectively have knowledge of radon’s physical and chemical properties, toxicokinetics, key health endpoints, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.
This page is intentionally blank.
# CONTENTS

**DISCLAIMER** ................................................................. ii
**UPDATE STATEMENT** ...................................................... iii
**FOREWORD** ................................................................. v
**QUICK REFERENCE FOR HEALTH CARE PROVIDERS** ........ vii
**CONTRIBUTORS** ............................................................ xi
**PEER REVIEW** ............................................................... xiii
**CONTENTS** ..................................................................... xv
**LIST OF FIGURES** .......................................................... xix
**LIST OF TABLES** ........................................................... xxi

1. PUBLIC HEALTH STATEMENT ......................................... 1
   1.1 WHAT IS RADON? .......................................................... 2
   1.2 WHAT HAPPENS TO RADON WHEN IT ENTERS THE ENVIRONMENT? .................. 3
   1.3 HOW MIGHT I BE EXPOSED TO RADON AND RADON PROGENY? .................. 3
   1.4 HOW CAN RADON AND RADON PROGENY ENTER AND LEAVE MY BODY? .......... 4
   1.5 HOW CAN RADON AND RADON PROGENY AFFECT MY HEALTH? ................... 5
   1.6 HOW CAN RADON AND RADON PROGENY AFFECT CHILDREN? .................... 5
   1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO RADON AND RADON PROGENY? .......... 6
   1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO RADON AND RADON PROGENY? .......... 6
   1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? ................ 6
   1.10 WHERE CAN I GET MORE INFORMATION? ....................................................... 8

2. RELEVANCE TO PUBLIC HEALTH ....................................... 9
   2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO RADON IN THE UNITED STATES .................. 9
   2.2 SUMMARY OF HEALTH EFFECTS .......................................................... 10
   2.3 MINIMAL RISK LEVELS (MRLs) .............................................................. 12

3. HEALTH EFFECTS ....................................................... 15
   3.1 INTRODUCTION .............................................................. 15
   3.2 DISCUSSION OF HEALTH EFFECTS OF RADON BY ROUTE OF EXPOSURE .......... 18
      3.2.1 Inhalation Exposure .............................................................. 20
         3.2.1.1 Death .................................................................................. 31
         3.2.1.2 Systemic Effects ................................................................. 32
         3.2.1.3 Immunological and Lymphoreticular Effects ......................... 34
         3.2.1.4 Neurological Effects .......................................................... 34
         3.2.1.5 Reproductive Effects ......................................................... 34
         3.2.1.6 Developmental Effects ....................................................... 35
         3.2.1.7 Cancer ............................................................................... 35
      3.2.2 Oral Exposure ............................................................................. 42
         3.2.2.1 Death .................................................................................. 42
         3.2.2.2 Systemic Effects ................................................................. 42
         3.2.2.3 Immunological and Lymphoreticular Effects ......................... 42
         3.2.2.4 Neurological Effects .......................................................... 42
         3.2.2.5 Reproductive Effects ......................................................... 42
         3.2.2.6 Developmental Effects ....................................................... 42

3.2.2.7 Cancer .................................................................................................................. 42
3.2.3 Dermal Exposure ........................................................................................................ 43
3.2.3.1 Death ....................................................................................................................... 43
3.2.3.2 Systemic Effects ...................................................................................................... 43
3.2.3.3 Immunological and Lymphoreticular Effects .......................................................... 43
3.2.3.4 Neurological Effects ............................................................................................... 43
3.2.3.5 Reproductive Effects .............................................................................................. 43
3.2.3.6 Developmental Effects .......................................................................................... 43
3.2.3.7 Cancer ..................................................................................................................... 43
3.3 GENOTOXICITY ........................................................................................................... 45
3.4 TOXICOKINETICS ..................................................................................................... 49
3.4.1 Absorption ................................................................................................................ 51
3.4.1.1 Inhalation Exposure ............................................................................................... 51
3.4.1.2 Oral Exposure ......................................................................................................... 54
3.4.1.3 Dermal Exposure ................................................................................................... 55
3.4.2 Distribution ................................................................................................................ 56
3.4.2.1 Inhalation Exposure ............................................................................................... 56
3.4.2.2 Oral Exposure ......................................................................................................... 57
3.4.2.3 Dermal Exposure ................................................................................................... 58
3.4.3 Metabolism ................................................................................................................ 58
3.4.4 Elimination and Excretion .......................................................................................... 58
3.4.4.1 Inhalation Exposure ............................................................................................... 58
3.4.4.2 Oral Exposure ......................................................................................................... 59
3.4.4.3 Dermal Exposure ................................................................................................... 60
3.4.4.4 Other Routes of Exposure ...................................................................................... 60
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .... 60
3.5 MECHANISMS OF ACTION ......................................................................................... 82
3.5.1 Pharmacokinetic Mechanisms .................................................................................. 82
3.5.2 Mechanisms of Toxicity ............................................................................................ 84
3.5.3 Animal-to-Human Extrapolations .............................................................................. 88
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS ......................... 88
3.7 CHILDREN’S SUSCEPTIBILITY ..................................................................................... 89
3.8 BIOMARKERS OF EXPOSURE AND EFFECT ................................................................ 91
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Radon and Radon Progeny .... 92
3.8.2 Biomarkers Used to Characterize Effects Caused by Radon and Radon Progeny ...... 92
3.9 INTERACTIONS WITH OTHER CHEMICALS ................................................................ 93
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ................................................. 96
3.11 METHODS FOR REDUCING TOXIC EFFECTS ............................................................... 96
3.11.1 Reducing Peak Absorption Following Exposure ..................................................... 97
3.11.2 Reducing Body Burden ............................................................................................ 97
3.11.3 Interfering with the Mechanism of Action for Toxic Effects ................................... 97
3.12 ADEQUACY OF THE DATABASE ................................................................................. 98
3.12.1 Existing Information on Health Effects of Radon .................................................. 98
3.12.2 Identification of Data Needs .................................................................................... 100
3.12.3 Ongoing Studies ....................................................................................................... 105

4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION ........................................ 107
4.1 CHEMICAL IDENTITY .................................................................................................. 107
4.2 PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES ........................................ 107
This page is intentionally blank.
LIST OF FIGURES

3-1. Cumulative Absolute Risk of Death from Lung Cancer by Age 75 Years Versus Long-Term Average Radon Concentration at Home for Continuing Smokers, Ex-Smokers, and Lifelong Nonsmokers in the United Kingdom ................................................................. 40

3-2. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance ................................................................................................................. 62

3-3. Compartment Model to Represent Particle Deposition and Time-Dependent Particle Transport in the Respiratory Tract .................................................................................................................. 66

3-4. Reaction of Gases or Vapors at Various Levels of the Gas-Blood Interface ........................................... 68

3-5. The Human Respiratory Tract Model: Absorption into Blood ................................................................. 74

3-6. Simplified Version of the Human Respiratory Tract Model (HRTM) ......................................................... 76

3-7. Schematic Diagram of the NAS (1999b) PBPK Model Developed to Describe the Fate of Radon within Systemic Tissues ..................................................................................................................... 78


3-9. Conceptual Model of the Biology Leading From Alpha Irradiation of Cells by Radon and Radon Progeny to Tumor Development .................................................................................................. 86

3-10. Existing Information on Health Effects of Radon .................................................................................. 99

4-1. $^{238}\text{U}$ Decay Series Showing Sources and Decay Products ........................................................................ 112

4-2. $^{232}\text{Th}$ Decay Series Showing Sources and Decay Products .......................................................................... 113

4-3. $^{235}\text{U}$ Decay Series Showing Sources and Decay Products ............................................................................. 114
This page is intentionally blank.
## LIST OF TABLES

3-1. Selected Characteristics and Exposure Data for Individual Miner Cohort Studies Included in the Analysis of Pooled Data from the Individual Studies, and Lung Cancer Mortality Rates and Relative Risks by Cumulative WLM for Pooled Data .......................................................... 24

3-2. Selected Results from Analysis of Pooled Data from 11 Mining Cohorts, Based on Deciles of Case Exposures That Were Each Under 100 WLM .................................................................................. 25

3-3. ORs for Lung Cancer from Combined Analysis of Two China Residential Case-Control Studies (Using a 5–30-Year Exposure Time Window) .................................................................................. 27

3-4. Selected Characteristics of Study Subjects, Exposure Estimates, and ORs for Lung Cancer from Combined Analysis of Seven North American Residential Case-Control Studies (Using a 5–30-Year Exposure Time Window) ........................................................................ 29

3-5. Relative Risk and Excess Relative Risk of Lung Cancer by Radon Level in Homes 5–34 Years Previously, Estimated from the Pooled Data for 13 European Residential Case-Control Studies .... 30

3-6. Genotoxicity of Radon and Radon Progeny \textit{In Vivo} ........................................................................................................... 46

3-7. Genotoxicity of Radon and Radon Progeny \textit{In Vitro} ........................................................................................................... 47

3-8. Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity ............................................................................................................................................... 67

3-9. Reference Values of Parameters for the Compartment Model to Represent Time-Dependent Particle Transport from the Human Respiratory Tract .................................................................................. 70

3-10. Parameters in the NAS (1999b) PBPK Model ............................................................................................................ 80


4-1. Chemical Identity of Radon ................................................................................................................................................. 108

4-2. Physical, Chemical, and Radiological Properties of Radon ................................................................................................. 109

4-3. Radioactive Properties of \(^{222}\)Rn and Its Short-lived Progeny ............................................................................................... 111

7-1. Analytical Methods for Determining Radon Progeny in Biological Samples ........................................................................ 148

7-2. Analytical Methods for Determining Radon and Progeny in Environmental Samples ........................................................................... 154

8-1. Regulations, Advisories, and Guidelines Applicable to Radon ................................................................................................. 161